These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 28621425)

  • 1. Epigenetic mechanism of FMR1 inactivation in Fragile X syndrome.
    Hecht M; Tabib A; Kahan T; Orlanski S; Gropp M; Tabach Y; Yanuka O; Benvenisty N; Keshet I; Cedar H
    Int J Dev Biol; 2017; 61(3-4-5):285-292. PubMed ID: 28621425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CGG-repeat dynamics and
    Zhou Y; Kumari D; Sciascia N; Usdin K
    Mol Autism; 2016; 7():42. PubMed ID: 27713816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FMR1 epigenetic silencing commonly occurs in undifferentiated fragile X-affected embryonic stem cells.
    Avitzour M; Mor-Shaked H; Yanovsky-Dagan S; Aharoni S; Altarescu G; Renbaum P; Eldar-Geva T; Schonberger O; Levy-Lahad E; Epsztejn-Litman S; Eiges R
    Stem Cell Reports; 2014 Nov; 3(5):699-706. PubMed ID: 25418717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promoter-bound trinucleotide repeat mRNA drives epigenetic silencing in fragile X syndrome.
    Colak D; Zaninovic N; Cohen MS; Rosenwaks Z; Yang WY; Gerhardt J; Disney MD; Jaffrey SR
    Science; 2014 Feb; 343(6174):1002-5. PubMed ID: 24578575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA Methylation, Mechanisms of
    Nobile V; Pucci C; Chiurazzi P; Neri G; Tabolacci E
    Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33669384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring for Epigenetic Modifications at the FMR1 Locus.
    Epsztejn-Litman S; Eiges R
    Methods Mol Biol; 2019; 1942():29-48. PubMed ID: 30900173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndrome.
    Brasa S; Mueller A; Jacquemont S; Hahne F; Rozenberg I; Peters T; He Y; McCormack C; Gasparini F; Chibout SD; Grenet O; Moggs J; Gomez-Mancilla B; Terranova R
    Clin Epigenetics; 2016; 8():15. PubMed ID: 26855684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential epigenetic modifications in the FMR1 gene of the fragile X syndrome after reactivating pharmacological treatments.
    Tabolacci E; Pietrobono R; Moscato U; Oostra BA; Chiurazzi P; Neri G
    Eur J Hum Genet; 2005 May; 13(5):641-8. PubMed ID: 15741991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An origin of DNA replication in the promoter region of the human fragile X mental retardation (FMR1) gene.
    Gray SJ; Gerhardt J; Doerfler W; Small LE; Fanning E
    Mol Cell Biol; 2007 Jan; 27(2):426-37. PubMed ID: 17101793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of FMR1 hypermethylation in somatic cell heterokaryons.
    Stoyanova V; Rossetti S; VAN Unen L; Oostra BA; Hoogeveen AT
    FASEB J; 2004 Dec; 18(15):1964-6. PubMed ID: 15377638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FMR1 CGG repeat lengths mediate different regulation of reporter gene expression in comparative transient and locus specific integration assays.
    Sølvsten C; Nielsen AL
    Gene; 2011 Oct; 486(1-2):15-22. PubMed ID: 21767618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.
    Jacquemont S; Curie A; des Portes V; Torrioli MG; Berry-Kravis E; Hagerman RJ; Ramos FJ; Cornish K; He Y; Paulding C; Neri G; Chen F; Hadjikhani N; Martinet D; Meyer J; Beckmann JS; Delange K; Brun A; Bussy G; Gasparini F; Hilse T; Floesser A; Branson J; Bilbe G; Johns D; Gomez-Mancilla B
    Sci Transl Med; 2011 Jan; 3(64):64ra1. PubMed ID: 21209411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos.
    Eiges R; Urbach A; Malcov M; Frumkin T; Schwartz T; Amit A; Yaron Y; Eden A; Yanuka O; Benvenisty N; Ben-Yosef D
    Cell Stem Cell; 2007 Nov; 1(5):568-77. PubMed ID: 18371394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A distinct DNA-methylation boundary in the 5'- upstream sequence of the FMR1 promoter binds nuclear proteins and is lost in fragile X syndrome.
    Naumann A; Hochstein N; Weber S; Fanning E; Doerfler W
    Am J Hum Genet; 2009 Nov; 85(5):606-16. PubMed ID: 19853235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The distribution of repressive histone modifications on silenced FMR1 alleles provides clues to the mechanism of gene silencing in fragile X syndrome.
    Kumari D; Usdin K
    Hum Mol Genet; 2010 Dec; 19(23):4634-42. PubMed ID: 20843831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of Histone Deacetylases Are Weak Activators of the
    Dolskiy AA; Pustylnyak VO; Yarushkin AA; Lemskaya NA; Yudkin DV
    Biomed Res Int; 2017; 2017():3582601. PubMed ID: 29209628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversion of FMR1 Methylation and Silencing by Editing the Triplet Repeats in Fragile X iPSC-Derived Neurons.
    Park CY; Halevy T; Lee DR; Sung JJ; Lee JS; Yanuka O; Benvenisty N; Kim DW
    Cell Rep; 2015 Oct; 13(2):234-41. PubMed ID: 26440889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Animal model for fragile X syndrome.
    Oostra BA; Hoogeveen AT
    Ann Med; 1997 Dec; 29(6):563-7. PubMed ID: 9562525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone modifications depict an aberrantly heterochromatinized FMR1 gene in fragile x syndrome.
    Coffee B; Zhang F; Ceman S; Warren ST; Reines D
    Am J Hum Genet; 2002 Oct; 71(4):923-32. PubMed ID: 12232854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular diagnosis of fragile X syndrome using methylation sensitive techniques in a cohort of patients with intellectual disability.
    Chaudhary AG; Hussein IR; Abuzenadah A; Gari M; Bassiouni R; Sogaty S; Lary S; Al-Quaiti M; Al Balwi M; Al Qahtani M
    Pediatr Neurol; 2014 Apr; 50(4):368-76. PubMed ID: 24630283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.